Novartis India enterprise value

Share price at each year-end
Tap a line for its trendCurrentlast closeFY25Mar 2025FY24Mar 2024FY23Mar 2023
52.152.145.019.4
0.00.01.4—
−52.1−52.1−43.6—
785785746—
0.0%0.0%0.2%—
Reference items — trailing FY values
356356335379
91.491.465.365.1
89.289.262.759.0
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

NOVARTIND₹1,821.40

Novartis India Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLPARNAXLABSGRLSHUKRAPHARSUNLOC
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
Current
last close
- Cash, Equiv & ST Investments19.445.052.152.1
+ Total Debt—1.40.00.0
Net Debt (memo)—-43.6-52.1-52.1
Total Capital—746.2785.0785.0
Total Debt/Total Capital—0.190.000.00
Reference Items — Trailing FY Values
Sales378.7335.1356.3356.3
EBITDA65.165.391.491.4
EBIT59.062.789.289.2
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.